Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05212623
Other study ID # LGYM(SJ)-2021-I
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 26, 2021
Est. completion date June 16, 2022

Study information

Verified date March 2022
Source Jiangsu Province Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this single-center, randomized, blinded, positive-controlled design, the investigators will assess the safety and immunogenicity of 2 doses of an inactivated quadrivalent influenza vaccine in children aged 6 to 35 months. About 120 healthy participants are planned to be enrolled, of who 60 participants were enrolled in the low-dose group and 60 participants were enrolled in the high-dose group. In the low-dose group, participants were randomly (2:1:1) assigned to receive a quadrivalent inactivated influenza vaccine (IIV4) at 0.25 mL including A/H1N1, A/H3N2, B/Victoria, and B/Yamagata, and a trivalent inactivated influenza vaccine (IIV3) at 0.25 mL including A/H1N1, A/H3N2 and B/Victoria, and IIV3 at 0.25 mL including A/H1N1, A/H3N2, and B/Yamagata. In the high-dose group, participants were randomly (2:1:1) assigned to receive IIV4 at 0.5 mL, and IIV3 at 0.25 mL including A/H1N1, A/H3N2, and B/Victoria, and IV3 at 0.25 mL including A/H1N1, A/H3N2, and B/Yamagata. Subjects receive 2 doses of influenza vaccine 4 weeks apart. The occurrence of adverse reactions within 30 minutes, the occurrence of adverse reactions within 28 days, and serious adverse events within 6 months after vaccination will be observed in all participants. For participants aged 24-35 months in each dose group, laboratory safety tests were measured before enrollment and on day 4 post each dose to assess any toxic effects. In addition, all subjects will be required to collect blood for HI antibody testing before the first dose of vaccination and 30 days after the second dose of vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date June 16, 2022
Est. primary completion date January 17, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 35 Months
Eligibility Inclusion Criteria: - Healthy infants and young children aged 6-35 months, provide vaccination certificate and birth medical certificate. - The subject or legal guardian can provide with informed consent and sign the informed consent form. - The subjects or legal guardians are able to and willing to use a thermometer, a scale and fill in a diary card/contact card as required, and be able to comply with the requirements of the clinical trial protocol to complete clinical research. Exclusion Criteria: 1. st dose: - Axillary temperature>37.0? - Participants aged 24-35 months, with abnormal blood routine, blood biochemical and urine routine indexes and judged by the researchers as having clinical significance. - Influenza within the past 3 months (confirmed clinically, serologically or microbiological). - Have previously received any influenza vaccine (registered or experimental) or planned to receive any influenza vaccine during the study. - Allergy to any component of the study vaccine, history of allergic reaction to eating eggs or using gentamicin sulfate. - History of severe allergies to any vaccines or drugs. - Preterm (delivered before 37 weeks of gestation), low birth weight (birth weight <2500g) infants (only for volunteers aged 6 months to 12 months). - Dystocia, suffocation rescue, nervous system damage history. - Congenital malformations or developmental disorders affecting organ function, genetic defects, severe malnutrition, etc.. - Acute illness, severe chronic illness, or acute exacerbation of chronic illness on the day of vaccination. - History of vaccination with the live attenuated vaccine within 14 days prior to vaccination and other vaccination within 7 days. - Those receiving immune enhancement or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days). - Have congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, or other autoimmune diseases. - History of asthma, unstable in the past two years requiring urgent treatment, hospitalization, intubation, oral or intravenous corticosteroids. - Receive blood or blood-related products within 3 months. - Have a medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. - History of coagulation abnormalities (eg, coagulation factor deficiency, coagulation disorder) - Plan to relocate before the end of the study or to be away from home for an extended period of time during scheduled study visits - Participating in or planning to participate in other clinical trials in the near future - Abnormal laboratory test indicators, except for minor abnormalities that have no clinical significance as judged by the doctor. - The investigator judges any situation that is inappropriate to participate in this clinical trial 2. nd dose: - Severe allergic reaction after the first dose of the vaccine. - Serious adverse reactions causally related to the first dose of the vaccine. - After the first vaccination, newly discovered or newly occurred do not meet the first-dose inclusion criteria or meet the first-dose exclusion criteria will be determined by the investigator whether to continue participating in the study. - Other reasons for exclusion in the opinion of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
quadrivalent influenza split vaccine
This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
quadrivalent influenza split vaccine
This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
Influenza virus split vaccine
This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
Influenza virus split vaccine
This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.

Locations

Country Name City State
China Jiangsu Province Centers for Disease Control and Prevention Nanjing Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Jiangsu Province Centers for Disease Control and Prevention Changchun Institute of Biological Products Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events within 7 days after each vaccination in the participants aged 6-35 months. (Including abnormal laboratory test indicators and clinical significance) Incidence of adverse events within 7 days after each vaccination in the participants aged 6-35 months. (Including abnormal laboratory test indicators and clinical significance) On day 7 after each dose
Secondary Incidence of adverse events from the first dose to 30 days after the second dose in the participants aged 6-35 months. Incidence of adverse events from the first dose to 30 days after the second dose in the participants aged 6-35 months. Time Frame: within 30 days after the second dose
Secondary Incidence of serious adverse events (SAE) till the 6 months after the second dose in the participants aged 6-35 months. Incidence of serious adverse events (SAE) till the 6 months after the second dose in the participants aged 6-35 months. within 6 months after the second dose
Secondary HI antibody-positive conversion rate in each group 30 days after the second vaccination in the participants aged 6-35 months. HI antibody-positive conversion rate in each group 30 days after the second vaccination in the participants aged 6-35 months. on day 30 after the second vaccination
Secondary Seroprotection rate 30 days after the second dose in each group in the participants aged 6-35 months. Seroprotection rate 30 days after the second dose in each group in the participants aged 6-35 months. on day 30 after the second vaccination
Secondary GMT of HI antibodies 30 days after the second dose of each group in the participants aged 6-35 months. GMT of HI antibodies 30 days after the second dose of each group in the participants aged 6-35 months. on day 30 after the second vaccination
Secondary GMI of HI antibodies 30 days after the second dose of each group in the participants aged 6-35 months. GMI of HI antibodies 30 days after the second dose of each group in the participants aged 6-35 months. on day 30 after the second vaccination
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A